EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Market data and deal flow

What is still missing from the market evidence?

Dose Diligence research deskSection 11 · Page 10 of 11Last updated 17 Nov 2026

This report establishes national scale, dated price references and recent activity. It does not establish:

  • The number of US provider networks in the target prescriber band that control partner selection.
  • Their active patient counts, route mix or negotiable medicine expenditure.
  • A representative distribution of clinic acquisition costs or pharmacy service fees.
  • Supplier-specific GLP-1 capacity, allocation or delivery performance by state.
  • Complete economics behind the announced manufacturer–telehealth arrangements.
  • A current national compounded-GLP-1 spending total or comprehensive legal clearance for a proposed preparation.
  • A verified universal offer for newly discussed multi-month Zepbound fills; no such price has been incorporated into the benchmark table.

The highest-value next research pass is a matched, redacted quotation and invoice panel from target providers. Pair it with product-specific supplier diligence and aggregate fulfillment data. That would convert public market context into a defensible clinic procurement benchmark.

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →